12.11.2012 Views

insight - Matrox

insight - Matrox

insight - Matrox

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

The drug discovery process not only develops new drugs that cure,<br />

control, or prevent disease . This process must also include rigorous<br />

testing for severe side effects . This is particularly true for drugs that<br />

are intended for long-term or even lifetime use, such as anti-rejection<br />

drugs for transplant patients .<br />

Long before human trials can proceed, drugs must be tested for their<br />

efficacy and safety . The Preclinical Safety unit at Novartis (Basel,<br />

Switzerland) has the responsibility of determining adverse side effects<br />

of all new molecular entities (drugs) in vitro (i .e ., in cultured cells)<br />

and in vivo (animal testing) . Besides other toxicological studies, the<br />

researchers perform genetic toxicology assays (tests) to assess the<br />

genotoxic potential of new drug candidates . Drug effects on mammalian<br />

cells are studied, using chromosomal abnormalities (besides other<br />

cellular and nuclear endpoints) to assess the compound’s potential<br />

hazards . When such abnormalities occur, it means that the drug in<br />

question has interacted with the cell’s genome . Dr . Wilfried Frieauff,<br />

Laboratory Manager of the Preclinical Safety unit says that when a<br />

statistically and biologically significant increase in these events are<br />

observed, there’s a potential for the drug candidate to induce cancer .<br />

Frieauff manages the labs, and he is responsible for the image analysis<br />

platform – its development, system maintenance, and support . The<br />

Preclinical Safety unit runs hundreds of tests annually on literally<br />

millions of cells . Given the numbers, it’s no surprise that the analysis<br />

process is one that benefits from automation .<br />

At the end of the 1980s, Frieauff’s lab began to use Leitz MIAS image<br />

analyzers for that purpose . But by the late 1990s, Dr . Frieauff realized<br />

that the systems were seriously outdated . “It was a stand-alone system<br />

that could not be part of a network . Replacement parts were no longer<br />

available,” he explains . These early image analysis systems had a<br />

maximum capacity of processing only 16 slides in a row . “Sometimes we<br />

would load the slides on Friday, and the system would finish and sit idling<br />

until Monday morning .” More importantly, Frieauff expected the future<br />

would bring more image analysis development projects and he “realized<br />

that it was time to totally re-engineer and modernize our image analysis .”<br />

Case Study: Novartis<br />

After extensive research of the market, Frieauff selected several<br />

components that would comprise the new ROBIAS, the Robotic Image<br />

Analysis System . ROBIAS is built from an electronically-driven Leica DM<br />

RXA/2 microscope mounted with a SONY DXC-390 color CCD camera<br />

that is connected to host PC with a <strong>Matrox</strong> Meteor-II/Multi-Channel<br />

frame grabber . An optional robotic slide feeder can automatically<br />

place up to 130 slides on the microscope’s stage for processing, which<br />

is performed by using custom-developed image analysis algorithms<br />

based on the <strong>Matrox</strong> Imaging Library .<br />

Automated microscopy<br />

Due to the subjective nature of manual microscopy and the increasing<br />

need for accurate, standardized results, image processing techniques<br />

have been used in microscopy for some time . Indeed, medical<br />

diagnostic and pharmaceutical applications need precise results<br />

– lives are at stake – and automated microscopy offers complete<br />

objectivity (thanks to image processing algorithms) and relieves the<br />

human eye of difficult and fatiguing tasks .<br />

The ROBIAS system performs specific cytogenetics assays (cell-genetic<br />

tests) that examine both in vitro and in vivo samples:<br />

• micronucleus test (MNT) in vivo (regulatory test to be conducted for<br />

drug registration)<br />

• comet assay in vivo<br />

• metaphase finding for chromosome aberration analysis (regulatory<br />

test to be conducted for drug registration )<br />

• MNT in vitro (for early genotoxicity screening)<br />

• comet assay in vitro (for early genotoxicity screening)<br />

• MNT in primary human lymphocytes (currently under development)<br />

By studying the cells’ DNA, the researchers can add evidence to a drug’s<br />

relative safety, or identify potential hazards . For the micronucleus<br />

test or the chromosome aberration analysis, the researchers look<br />

for chromosomal abnormalities which become visible when the cell<br />

passes through mitosis .<br />

The Robotic Image Analysis System (ROBIAS) is built from a electricpowered<br />

microscope and an optional robotic slide feeder .<br />

IMAGING INSIGHT Vol. 10 No. 1<br />

11

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!